Ophthalmology CDMOs
11 published
11 published CDMOs match Ophthalmology.
Locations in this set include United States, United Kingdom, China, India, Australia, and Brazil.
Capabilities that show up most often in this set: Formulation Development, Process Development, Stability Testing & Storage, CMC Analytical Development, and Sterile Fill-Finish & Aseptic Manufacturing.
Matching companies
Akums Drugs and Pharmaceuticals Ltd.India's largest CDMO with 15+ state-of-the-art facilities and 30% domestic market share, manufacturing 4,100+ formulations across tablets, capsules, injectables, APIs, and specialty dosage forms under WHO-GMP, USFDA, EU-GMP, and TGA compliance.
AltasciencesMid-size early phase CRO/CDMO in Canada and the U.S. offering preclinical safety testing, clinical pharmacology (Phase I–II), bioanalysis, research services, and manufacturing with integrated capabilities.
Amneal PharmaceuticalsU.S.-based biopharmaceutical company offering oral solid dosage, injectables, and API manufacturing with FDA-approved facilities across the U.S. and India, including advanced capabilities in lyophilization, aseptic processing, and oncology formulations.
Forge BiologicsDedicated AAV gene therapy CDMO with a 200,000+ sq. ft. cGMP facility featuring 20 suites and bioreactors up to 5,000L, supporting 60+ clients across 35+ indications with high-yield manufacturing and seamless regulatory compliance.
HitGen Inc.HitGen Inc. provides drug discovery services built on DNA-encoded library (DEL), fragment-based (FBDD/SBDD) and computational platforms for pharmaceutical and biotech clients. The company also offers oligonucleotide CDMO services and reports serving more than 600 clients globally.
IDT AustraliaIDT Australia is a cGMP CDMO delivering end-to-end pharmaceutical development and manufacturing services from active pharmaceutical ingredients to finished dosage forms, with expertise in small molecule APIs, specialty orals, advanced therapies, and integrated regulatory support.
MedpharmSpecialized CDMO for topical, transdermal, and transepithelial drug products offering formulation development, analytical testing, process scale-up, and GMP manufacturing from early development through commercialization.
Mytos Inc.Mytos is an automated CDMO for regenerative medicines, using its iDEM platform to produce stem-cell derived therapies. The company says its automation lets clients scale in months rather than years at lower cost per batch.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Unither PharmaceuticalsGlobal CDMO specializing in sterile and non-sterile liquid manufacturing, including Blow-Fill-Seal (BFS) single-dose technology with over 5 billion annual capacity, plus formulation development, analytical services, and ophthalmic expertise across six production sites.
Markdown mirror: /indications/ophthalmology.md